



Turning innovation into value



01

Actelion - From ambition...



From left:


André J. Mueller, Vice Chairman of the Board of Directors, former Chief Financial Officer

Dr. Jean-Paul Clozel, Chief Executive Officer and Member of the Board of Directors

Dr. Martine Clozel, Senior Vice President, Head of Drug Discovery, Pharmacology and Preclinical Development


Dr. Walter Fischli, Senior Vice President, Head of Drug Discovery, Biology

Dr. Thomas Widmann, former Chief Executive Officer



Endothelin Receptor Antagonist

In 1990, a research team at Roche discovered the first endothelin receptor antagonists (ERAs), blocking the most powerful constrictor of blood vessels known in humans. Recognizing the potential of the ERAs, the researchers founded Actelion in December 1997. Actelion's founders shared a vision to create a special type of company - an organization with experienced, motivated people and a work environment that encouraged innovation and creativity with the aim to discover, develop and market novel medicines that fundamentally improve patients' lives.



... to realization 10 years on

Today, Actelion is one of the most successful biopharmaceutical companies, combining the innovation, entrepreneurial spirit and flexibility of biotech with the financial, risk management, regulatory and commercial discipline of a large pharmaceutical company. With its headquarters based in Allschwil, Switzerland, and affiliates in over 20 countries worldwide, Actelion has a proven ability to discover new compounds, and to move compounds from research through development to global commercialization.



Our products

Transforming medical care

Actelion's lead product is Tracleer® (bosentan), an oral dual endothelin receptor antagonist. Tracleer® is approved for the treatment of pulmonary arterial hypertension (PAH), a rare, chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. It is also approved to reduce the number of digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Ventavis® (iloprost), an inhaled formulation of a prostacyclin, is approved for the treatment of pulmonary arterial hypertension. Ventavis®, the only inhaled PAH therapy on the US market, has a mode of action that perfectly complements Tracleer®.

Zavesca® (miglustat) is currently the only approved oral treatment for mild to moderate forms of type 1 Gaucher's disease, a rare and debilitating metabolic disorder, and used in patients for whom enzyme replacement therapy is unsuitable.







03

Our Research & Development

The next wave of innovation



Actelion's research focuses on the design and synthesis of novel low-molecular weight compounds and primarily two families of drug targets: GPCRs and aspartyl proteases, which play important roles in a number of major human diseases. By establishing expertise in and focusing our discovery and development efforts on these research platforms, Actelion generates a stream of product candidates to treat a variety of illnesses in therapeutic areas such as anti-allergic, antibacterial, cardiovascular, central nervous system, and immunology.

Actelion develops its product candidates in clinical programs. Our development priorities are driven by medical need. Actelion's development function concentrates on innovative compounds and on expanding the potential indications for our marketed drugs. We manage our products through life-cycle teams to rapidly move a drug from inception to commercialization and beyond.



04

Prepared for the future

Reaching for ambitious targets



Actelion's four Strategic Principles describe the fundamental priorities required to reach the long-term business objective - to become one of the top biopharmaceutical companies in the world.

These principles are:

Follow innovation where it leads

We pursue internal and external R&D opportunities while balancing the perspectives of scientific merit, unmet medical need and commercial potential.

Retain the value of innovation


We develop projects as far as possible within the company, thereby considering partnerships for strategic and/or financial benefit. When partnerships are implemented, we strive to book an appropriate proportion of sales to further expand R&D.

Excel in sales and marketing

It is our aim to expand the innovative, highly experienced commercial team to drive growth.

Retain core values, culture and independence

We seek to enhance our culture of Innovation, Trust and Teamwork and Open Communication to foster an enthusiastic and stimulating environment for employees and company development. At the same time we want to maintain our Results Driven Orientation.



05

Actelion's culture

Key to success

Actelion's achievements to date are based on the company's ideals of the early days, expressed in our Core Values:

Innovation

Across the business, our employees use innovation and creativity to find better ways to perform their role and achieve their goals. This is combined with a "patient-first" mindset.

Open Communication

Information is shared across all functions within the company. The information flow across departments ensures timeliness, efficiency and effective use of resources.

Trust & Teamwork

Actelion has high ethical standards and a respect for all - employees, patients, clinicians and business partners. A belief that working together will yield greater results is pervasive.

Results Driven

A 'keep it simple' philosophy streamlines the business, supports decision-making and finds solutions that bring all stakeholders to successful outcomes: providing innovative, life-changing drugs to patients.

06

Our people

Securing a successful future

Actelion's business momentum is mirrored in the growing number of employees. Our employees represent the best professional attributes, blending biotech innovation with pharmaceutical discipline and the highest ethical standards.

We continue to place high priority on attracting, developing and retaining highly talented people. Employees who identify with the goals and values of our company have transformed the vision of Actelion's founders into reality: People with passion and expertise are paving the way to our future success.



